LUMINITA MANN: Open Payments
NPI 1326338450 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,427 in 86 payments from 19 companies in 2025. Trend: 2023 $2,522 · 2024 $1,531 · 2025 $1,427
Food & beverage: $1,427
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $222 |
| Amgen Inc. | 17 | $155 |
| IBSA Pharma Inc. | 14 | $137 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $125 |
| ABBVIE INC. | 6 | $109 |
| Novartis Pharmaceuticals Corporation | 5 | $96 |
| Abbott Laboratories | 4 | $92 |
| SANOFI-AVENTIS U.S. LLC | 2 | $67 |
| Corcept Therapeutics | 2 | $65 |
| RECORDATI_RARE_DISEASES_INC. | 2 | $60 |
Products named: MOUNJARO, Tirosint, Kerendia, SYNTHROID, LEQVIO, FREESTYLE LIBRE 3, TZIELD, Korlym.
Industry payments across CA — which companies pay providers there.
